Literature DB >> 17638533

An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays.

Fabian Zanella1, Aranzazú Rosado, Fernando Blanco, Beric R Henderson, Amancio Carnero, Wolfgang Link.   

Abstract

Intracellular localization is essential for the regulated activity of many signaling molecules associated with disease-relevant pathways. High content screening is a powerful technology to monitor the impact of small molecules or interfering RNAs on translocation of proteins within intact cells. Several assays have been developed to measure the nucleocytoplasmic shuttling of proteins like nuclear factor kappaB, FoxO, or nuclear factor of activated T-cells involved in distinct signaling networks. However, since all these proteins bear a leucine-rich nuclear export signal (NES), modulators of the NES-dependent export machinery can lead to misinterpretation of the assay readout. Here we report the generation of U2nesRELOC, a cell-based system for the identification of nuclear export inhibitors and specific silencers of the nuclear export machinery, and its adaptation to high throughput screening. The assay is based on mammalian cells stably expressing green fluorescent protein (GFP)-labeled Rev protein, which contains a strong heterologous NES. The fluorescent signal of untreated U2nesRELOC cells localizes exclusively to the cytoplasm. Upon treatment with the nuclear export inhibitor leptomycin B the GFP-labeled reporter protein accumulates rapidly in the cell nucleus. The assay has been adapted to 96-multiwell format and fully automated. Pilot experiments with a panel of 50 test compounds using three different concentrations per compound resulted in very consistent data sets with excellent reproducibility and an average Z' value of 0.76. In summary, U2nesRELOC is a cell-based nuclear export assay suitable for high throughput screening, providing counterscreens for pathway deconvolution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638533     DOI: 10.1089/adt.2007.058

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  14 in total

1.  Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts.

Authors:  Fabian Zanella; Amancio Carnero
Journal:  EMBO Rep       Date:  2008-09       Impact factor: 8.807

2.  Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.

Authors:  Teresa G Granda; David Cebrián; Sonia Martínez; Patricia Villanueva Anguita; Estela Casas López; Wolfgang Link; Teresa Merino; Joaquín Pastor; Beatriz G Serelde; Sandra Peregrina; Irene Palacios; Maria Isabel Albarran; Antonio Cebriá; Milagros Lorenzo; Patricia Alonso; Jesús Fominaya; Ana Rodríguez López; James R Bischoff
Journal:  Invest New Drugs       Date:  2012-05-24       Impact factor: 3.850

3.  Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.

Authors:  Wolfgang Link; Julen Oyarzabal; Beatriz G Serelde; Maria Isabel Albarran; Obdulia Rabal; Antonio Cebriá; Patricia Alfonso; Jesus Fominaya; Oliver Renner; Sandra Peregrina; David Soilán; Plácido A Ceballos; Ana-Isabel Hernández; Milagros Lorenzo; Paolo Pevarello; Teresa G Granda; Guido Kurz; Amancio Carnero; James R Bischoff
Journal:  J Biol Chem       Date:  2009-08-18       Impact factor: 5.157

4.  Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.

Authors:  Stefan Baertschi; Nina Baur; Valerie Lueders-Lefevre; Johannes Voshol; Hansjoerg Keller
Journal:  J Biol Chem       Date:  2014-07-10       Impact factor: 5.157

5.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Patrizia Sanita; Flora Vitale; Francesco Marampon; Luca Ventura; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  BMC Cancer       Date:  2015-12-01       Impact factor: 4.430

Review 6.  Increasing the Content of High-Content Screening: An Overview.

Authors:  Shantanu Singh; Anne E Carpenter; Auguste Genovesio
Journal:  J Biomol Screen       Date:  2014-04-07

7.  A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling.

Authors:  Aranzazú Rosado; Fabian Zanella; Beatriz Garcia; Amancio Carnero; Wolfgang Link
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

8.  Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators.

Authors:  Fabian Zanella; Aranzazú Rosado; Beatriz Garcia; Amancio Carnero; Wolfgang Link
Journal:  BMC Cell Biol       Date:  2009-02-25       Impact factor: 4.241

9.  Hypoxia enhances chondrogenesis and prevents terminal differentiation through PI3K/Akt/FoxO dependent anti-apoptotic effect.

Authors:  Hsieh-Hsing Lee; Chia-Chi Chang; Ming-Jium Shieh; Jung-Pan Wang; Yi-Te Chen; Tai-Horng Young; Shih-Chieh Hung
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

Review 10.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.